Neuroendocrine Breast Cancer. Clinical Observation. Personalized Approach

Abstract

Introduction. Neuroendocrine breast tumors represent a rare subtype of breast cancer, accounting for less than 1 % of all neuroendocrine neoplasms. Starting from their pathology definition, and going through their prevalence, prognosis and treatment, our knowledge is still really uncertain.Materials and methods. The article presents a rare clinical observation of a neuroendocrine breast tumor. A breast fibroadenoma was diagnosed at the initial diagnosis stage in a private clinic; after a surgical treatment and further morphological study, it was estimated: a diagnosis of Cancer in situ of the left breast T1N0M0, stage I. Next, 3D-conformal remote radiation therapy was performed on the area of the left breast.Results and discussion. After conducting positron emission tomography, multiple metastases were detected in the lymph nodes, bones, and liver. Additionally, micropreparations were consulted at the Federal Reference Center in St. Petersburg and at an independent third-party molecular biological laboratory in Germany (Munich). Given all the instrumental, molecular biological, histological and immunohistochemical studies of the patient, an individual regimen of drug therapy was selected.Conclusion. After 18 months of personalized drug therapy, we observed a positive trend and a significant decrease in metabolic activity according to positron emission tomography.

Effectiveness of Ophtascan Screening in Lubumbashi. Pilot Study on Screening for Cancer and Type 2 Diabetes

“…In Africa, the low level of medicalization and the difficulties in accessing health services make this condition less known and the diagnosis late, sometimes even undiagnosed [10]. We can see that almost all the cancers targeted by the OPHTASCAN program have been detected already at the precancerous stage; which corresponds to the discoveries of Professor Gantsev, a renowned Russian oncologist [11] on "cancer without tumor". The idea of using Ophtascan MC is based on the principle of screening, that is to say the detection of cancer in the early stages or precancerous conditions in people who are not registered as cancer patients: they have never been diagnosed and have not been treated for cancer.…”